• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

arzerra (ofatumumab) - Articles and news items

FDA approves Genmab’s ofatumumab for relapsed CLL

Industry news / 31 August 2016 / Niamh Louise Marriott, Digital Content Producer

Approval is supported by the Phase III complement study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL…

 

Webinar: SIFT-MS: A New Tool for Impurity Profiling in Pharmaceutical ProductsLEARN MORE
+ +